Abstract:LKB1 (liver kinase B1) is a master regulator of several processes such as metabolism, proliferation, cell polarity and immunity. About one third of non-small cell lung cancers (NSCLCs) present LKB1 alterations, which almost invariably lead to protein loss, resulting in the absence of a potential druggable target. In addition, LKB1-null tumors are very aggressive and resistant to chemotherapy, targeted therapies and immune checkpoint inhibitors (ICIs). In this review, we report and comment strategies that exploit peculiar co-vulnerabilities to effectively treat this subgroup of NSCLCs. LKB1 loss leads to an enhanced metabolic avidity, and treatments inducing metabolic stress were successful in inhibiting tumor growth in several preclinical models. Biguanides, by compromising mitochondria and reducing systemic glucose availability, and the glutaminase inhibitor telaglenastat (CB-839), inhibiting glutamate production and reducing carbon intermediates essential for TCA cycle progression, have provided the most interesting results and entered different clinical trials enrolling also LKB1-null NSCLC patients. Nutrient deprivation has been investigated as an alternative therapeutic intervention, giving rise to interesting results exploitable to design specific dietetic regimens able to counteract cancer progression. Other strategies aimed at targeting LKB1-null NSCLCs exploit its pivotal role in modulating cell proliferation and cell invasion. Several inhibitors of LKB1 downstream proteins, such as mTOR, MEK, ERK and SRK/FAK, resulted specifically active on LKB1-mutated preclinical models and, being molecules already in clinical experimentation, could be soon proposed as a specific therapy for these patients. In particular, the rational use in combination of these inhibitors represents a very promising strategy to prevent the activation of collateral pathways and possibly avoid the potential emergence of resistance to these drugs. LKB1-null phenotype has been correlated to ICIs resistance but several studies have already proposed the mechanisms involved and potential interventions. Interestingly, emerging data highlighted that LKB1 alterations represent positive determinants to the new KRAS specific inhibitors response in KRAS co-mutated NSCLCs. In conclusion, the absence of the target did not block the development of treatments able to hit LKB1-mutated NSCLCs acting on several fronts. This will give patients a concrete chance to finally benefit from an effective therapy.

Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α

LKB1 and Cancer: the Dual Role of Metabolic Regulation.

Lkb1 is indispensable for skeletal muscle development, regeneration, and satellite cell homeostasis.

The tumor suppressor gene lkb1 is essential for glucose homeostasis during zebrafish early development

Posttranslational regulation of liver kinase B1 in human cancer

The Protein Kinase LKB1 Promotes Self‐renewal and Blocks Invasiveness in Glioblastoma

Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy

Cytoplasmic Liver Kinase B1 Promotes the Growth of Human Lung Adenocarcinoma by Enhancing Autophagy.

Deletion of Endothelial Cell-Specific Liver Kinase B1 Increases Angiogenesis and Tumor Growth Via Vascular Endothelial Growth Factor

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

Enhanced Expression of LKB1 in Breast Cancer Cells Attenuates Angiogenesis, Invasion, and Metastatic Potential

Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function.

LKB1 and lung cancer: more than the usual suspects

Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase As a Target in LKB1-mutant Lung Cancer.

LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors

LKB1 reduces ROS-mediated cell damage via activation of p38

Under-expression of LKB1 is Associated with Enhanced P38-Mapk Signaling in Human Hepatocellular Carcinoma.

LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer

LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism

Role of the LKB1/AMPK pathway in tumor invasion and metastasis of cancer cells (Review)

LKB1: Can We Target an Hidden Target? Focus on NSCLC